Underwater rocks of anti - helicobacter therapy
- 作者: Livzan M1
-
隶属关系:
- Omsk State Medical University
- 期: 卷 91, 编号 8 (2019)
- 页面: 141-147
- 栏目: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/33681
- DOI: https://doi.org/10.26442/00403660.2019.08.000386
- ID: 33681
如何引用文章
全文:
详细
The publication was prepared to systematize the data of the literature and our own research on the practice of effective eradication therapy of patients with HP-associated diseases. The most significant factors influencing the effective implementation of modern anti-Helicobacter therapy regimens should be adherence of physicians to the use of clinical guidelines, patient adherence to prescriptions and recommendations of specialists, as well as adherence to eradication treatment protocols.
作者简介
M Livzan
Omsk State Medical University
Email: mlivzan@yandex.ru
д.м.н., проф., зав. каф. факультетской терапии с курсом профессиональных болезней, ректор; ORCID: 0000-0002-6581-7017 Omsk, Russia
参考
- Maixner F, Krause-Kyora B, Turaev D, Herbig A, Hoopmann M.R, Hallows J.L, Kusebauch U, Vigl E.E, Malfertheiner P, Megraud F, O'Sullivan N, Cipollini G, Coia V, Samadelli M, Engstrand L, Linz B, Moritz R.L, Grimm R, Krause J., Nebel A, Moodley Y, Rattei T, Zink A. The 5300-year - old Helicobacter pylori genome of the Iceman. Science. 2016;351(6269):162-5. doi: 10.1126/science.aad2545
- Kao C.Y, Sheu B.S, Wu J.J. Helicobacter pylori infection: An overview of bacterial virulence factors and pathogenesis. Biomed J. 2016;39:14-23. doi: 10.1016/j.bj.2015.06.002
- Schistosomes, liver flukes and Helicobacter pylori IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1-241.
- Маев И.В., Бакулин И.Г., Курилович С.А., Бакулина Н.В., Андреев Н.Г., Голубев Н.Н. Helicobacter pylori и экстрагастродуоденальные заболевания: доказанные факты и предположения. Доказательная гастроэнтерология. 2018;7(3):45-59. doi: 10.17116/dokgastro2018703145
- Franceschi F, Gasbarrini A, Polyzos S.A, Kountouras J. Extragastric diseases and Helicobacter pylori. Helicobacter. 2015;20(Suppl 1):40-6. doi: 10.1111/hel.12256
- Kountouras J, Polyzos S.A, Katsinelos P, Zeglinas C, Artemaki F, Tzivras D, Vardaka E, Gavalas E, Romiopoulos I, Simeonidou C, Grigoriadis N, Kountouras C, Dardiotis E, Deretzi G. Cardio - cerebrovascular disease and Helicobacter pylori - related metabolic syndrome: We consider eradication therapy as a potential cardio - cerebrovascular prevention strategy. Int J Cardiol. 2017;229:17-8. doi: 10.1016/j.ijcard.2016.11.265
- Wang X.L, Zeng J, Yang Y, Xiong Y, Zhang Z.H, Qiu M, Yan X, Sun X.Y, Tuo Q.Z, Liu R, Wang J.Z. Helicobacter pylori filtrate induces Alzheimer - like tau hyperphosphorylation by activating glycogen synthase kinase-3β. J Alzheimers Dis. 2015;43:153-65. doi: 10.3233/JAD-140198
- Ricci V, Romano M, Boquet P. Molecular cross - talk between Helicobacter pylori and human gastric mucosa. World J Gastroenterol. 2011;17(11):1383-99. doi: 10.3748/wjg.v17.i11.1383
- Sugano K, Tack J, Kuipers E.J, Graham D.Y, El-Omar E.M, Miura S, Haruma K, Asaka M, Uemura N, Malfertheiner P, faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64:1353-67. doi: 10.1136/gutjnl-2015-309252
- Hunt R.H, Xiao S.D, Megraud F, Leon-Barua R, Bazzoli F, van der Merwe S, Vaz Coelho L.G, Fock M, Fedail S, Cohen H, Malfertheiner P, Vakil N, Hamid S, Goh K.L, Wong B.C, Krabshuis J, Le Mair A, World Gastroenterology Organization. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis. 2011;20:299-304.
- Malfertheiner P, Megraud F, O’Morain C.A, Gisbert J.P, Kuipers E.J, Axon A.T, Bazzoli F, Gasbarrini A, Atherton J, Graham D.Y, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar E.M; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection - the Maastricht V/Florence Consensus Report. Gut. 2017;66:6-30. doi: 10.1136/gutjnl-2016-312288
- Ивашкин В.Т., Маев И.В., Лапина Т.Л., Шептулин А.А., Трухманов А.С., Баранская Е.К., Абдулхаков Р.А., Алексеева О.П., Алексеенко С.А., Дехнич Н.Н., Козлов Р.С., Кляритская И.Л., Корочанская Н.В., Курилович С.А., Осипенко М.Ф., Симаненков В.И., Ткачев А.В., Хлынов И.Б., Цуканов В.В. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018;28(1):55-70.
- Chey W.D, Leontiadis G.I, Howden C.W, Moss S.F. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112(2):212-39. doi: 10.1038/ajg.2016.563
- Graham D.Y. Illusions regarding Helicobacter pylori clinical trials and treatment guidelines. Gut. 2017;66:2043-6. doi: 10.1136/gutjnl-2017-314744
- Zagari R.M, Rabitti S, Eusebi L.H, Bazzoli F. Treatment of Helicobacter pylori infection: A clinical practice update. Eur J Clin Invest. 2018;48:e12857. doi: 10.1111/eci.12857
- Бакулина Н.В., Симаненков В.И., Бакулин И.Г., Ильчишина Т.А. Распространенность хеликобактерной инфекции среди врачей. Экспериментальная и клиническая гастроэнтерология. 2017;12(148):20-4.
- Auttajaroon J, Chotivitayatarakorn P, Yamaoka Y, Vilaichone R.K. CYP2C19 Genotype, CagA Genotype and Antibiotic Resistant Strain of Helicobacter pylori Infection. Asian Pac J Cancer Prev. 2019;20(4):1243-7. doi: 10.31557/APJCP.2019.20.4.1243
- Маев И.В., Кучерявый Ю.А., Андреев Д.Н., Баркалова Е.В. Эрадикационная терапия инфекции Helicobacter pylori: обзор мировых тенденций. Терапевтический архив. 2014;86(3):94-9.
- Maev I.V, Andreev D.N, Kucheryavyi Yu.A, Dicheva D.T. Host factors influencing the eradication rate of Helicobacter pylori. World Applied Sci J. 2014;30:134-40. doi: 10.5829/idosi.wasj.2014.30.mett.61
- Boltin D, Dotan I, Birkenfeld S. Improvement in the implementation of Helicobacter pylori management guidelines among primary care physicians following a targeted educational intervention. Ann Gastroenterol. 2019;32(1):52-9. doi: 10.20524/aog.2018.0329
- Ribaldone D, Astegiano M, Pellicano R. Helicobacter pylori eradication: poor medical compliance from East to West of the world. Scand J Gastroenterol. 2018;53:265. doi: 10.1080/00365521.2018.1433231
- Осипенко М.Ф., Ливзан М.А., Бикбулатова Е.А. «Комплаентность» пациента как один из факторов, определяющих эффективность эрадикационной терапии. Терапевтический архив. 2014;86(2):27-31.
- O'Connor H.J. Helicobacter pylori and dyspepsia: physicians' attitudes, clinical practice, and prescribing habits. Aliment Pharmacol Ther. 2002;16(3):487-96. doi: 10.1046/j.1365-2036.2002.01183.x
- Бордин Д., Белоусова Н., Воробьёва Н., Зеленикин С. Язвенная болезнь: пути повышения эффективности эрадикации Helicobacter pylori. Врач. 2011;(4):43-7.
- Wang C.H, Liao S.T, Yang J, Li C.X, Yang Y.Y, Han R, Chen D.F, Lan C.H. Effects of daily telephone - based re - education before taking medicine on Helicobacter pylori eradication: A prospective single - center study from China. World J Gastroenterol. 2015;21(39):11179-84. doi: 10.3748/wjg.v21.i39.11179
- Tang H.L, Li Y, Hu Y.F, Xie H.G, Zhai S.D. Effects of CYP2C19 loss - of - function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitorbased triple therapy regimens: a meta - analysis of randomized clinical trials. Plos One. 2013;8:e62162. doi: 10.1371/journal.pone.0062162
- Елохина Е.В., Костенко М.Б., Ливзан М.А., Скальский С.В. Эффективность эрадикационной терапии у пациентов с язвенной болезнью, ассоциированной с Helicobacter pylori, в зависимости от генотипа лекарственного метаболизма ингибиторов протонной помпы. Экспериментальная и клиническая гастроэнтерология. 2015;115(3):31-3.
- Villoria A, Garcia P, Calvet X, Gisbert J.P, Vergara M. Meta - analysis: high - dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2008;28:868-77. doi: 10.1111/j.1365-2036.2008.03807.x
- Андреев Д.Н., Дичева Д.Т., Маев И.В. Возможности оптимизации эрадикационной терапии инфекции Helicobacter pylori в современной клинической практике. Терапевтический архив. 2017;89(2):84-90. doi: 10.17116/terarkh201789284-90
- Graham D.Y, Dore M.P. Update on the use of vonoprazan: a competitive acid blocker. Gastroenterology. 2018;154:462-6. doi: 10.1053/j.gastro.2018.01.018
- Yang X, Li Y, Sun Y, Zhang M, Guo C, Mirza I, et al. Vonoprazan: a novel and potent alternative in the treatment of acid - related diseases. Dig Dis Sci. 2018;63:302-11. doi: 10.1007/s10620-017-4866-6
- Kusunoki M, Yuki M, Ishitobi H, Kobayashi Y, Nagaoka M, Takahashi Y, Fukuba N, Komazawa Y, Shizuku T, Kinoshita Y. Effect of Age on Effectiveness of Vonoprazan in Triple Therapy for Helicobacter pylori Eradication. Intern Med. 2019 Feb 1. doi: 10.2169/internalmedicine.2233-18
- Sugimoto M, Yamaoka Y. Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan. Front Pharmacol. 2019;9:1560. doi: 10.3389/fphar.2018.01560
- Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium - competitive acid blocker, as a component of first - line and second - line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double - blind study. Gut. 2016;65(9):1439-46. doi: 10.1136/gutjnl-2015-311304
- Suzuki S, Gotoda T, Kusano C, Iwatsuka K, Moriyama M. The Efficacy and Tolerability of a Triple Therapy Containing a Potas - sium-Competitive Acid Blocker Compared With a 7-Day PPI- Based Low-Dose Clarithromycin Triple Therapy. Am J Gastroenterol. 2016;111(7):949-56. doi: 10.1038/ajg.2016.182
- Thung I, Aramin H, Vavinskaya V, Gupta S, Park J.Y, Crowe S.E, Valasek M.A. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43:514-33. doi: 10.1111/apt.13497
- Mégraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl A.M, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62:34-42. doi: 10.1136/gutjnl-2012-302254
- Hu Y, Zhu Y, Lu N.H. Novel and effective therapeutic regimens for Helicobacter pylori in an era of increasing antibiotic resistance. Front Cell Infect Microbiol. 2017;7:168. doi: 10.3389/fcimb.2017.00168
- Pellicano R, Zagari R.M, Zhang S, Saracco G.M, Moss S.F. Pharmacological considerations and step - by - step proposal for the treatment of Helicobacter pylori infection in the year 2018. Minerva Gastroenterol Dietol. 2018;64:310-21. doi: 10.23736/S1121-421X.18.02492-3
- Бордин Д.С., Эмбутниекс Ю.В., Вологжанина Л.Г. и др. Европейский регистр Helicobacter pylori (HP-EUREG): как изменилась клиническая практика в России с 2013 по 2018 год. Терапевтический архив. 2019;91(2):16-24. doi: 10.26442/00403660.2019.02.000156
- Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic - resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18:318-27. doi: 10.1016/S1473-3099(17)30753-3
- He X, Liao X, Li H, Xia W, Sun H. Bismuth - induced inactivation of ferric uptake regulator from Helicobacter pylori. Inorganic Chem. 2017;56:15041-8. doi: 10.1021/acs.inorgchem.7b02380
- Nishizawa T, Nishizawa Y, Yahagi N, et al. Effect of supplementation with rebamipide for Helicobacter pylori eradication therapy: A systematic review and meta - analysis. J Gastroenterol Hepatol. 2014;29(Suppl.4):20-4. doi: 10.1111/jgh.12769
- Szajewska H, Horvath A, Kołodziej M. Systematic review with meta - analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol Ther. 2015;41:1237-45. doi: 10.1111/apt.13214
- Zou J, Dong J, Yu X. Meta - analysis: Lactobacillus containing quadruple therapy versus standard triple first - line therapy for Helicobacter pylori eradication. Helicobacter. 2009;14:97-107. doi: 10.1111/j.1523-5378.2009.00716.x
- Sachdeva A, Nagpal J. Meta - analysis: efficacy of bovine lactoferrin in Helicobacter pylori eradication. Aliment Pharmacol Ther. 2009;29:720-30. doi: 10.1111/j.1365-2036.2009.03934.x
- Tong J.L, Ran Z.H, Shen J, Zhang C.X, Xiao S.D. Metaanalysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2007;25:155-68. doi: 10.1111/j.1365-2036.2006.03179.x
- Бордин Д.С., Войнован И.Н., Хомерики С.Г., Янова О.Б., Ким В.А., Быстровская Е.В., Шишин К.В. Эффективность и безопасность Lactobacillus Reuteri DSMZ17648 у инфицированных Helicobacter pylori. Лечащий врач. 2016;(5):106.
- Hardbower D.M, Peek R.M. Jr, Wilson K.T. At the Bench: Helicobacter pylori, dysregulated host responses, DNA damage, and gastric cancer. J Leukoc Biol. 2014;96(2):201-12. doi: 10.1189/jlb.4BT0214-099R
- Niikura R, Hayakawa Y, Hirata Y, Ogura K, Fujishiro M, Yamada A, Ushiku T, Konishi M, Fukayama M, Koike K. The Reduction in Gastric Atrophy after Helicobacter pylori Eradication Is Reduced by Treatment with Inhibitors of Gastric Acid Secretion. Int J Mol Sci. 2019;20(8). pii: E1913. doi: 10.3390/ijms20081913
- Ливзан М.А., Мозговой С.И., Кононов А.В. Гастрит после эрадикации Helicobacter pylori - простые следы или серьезные последствия? Лечащий врач. 2011;(7):7.
- Ливзан М.А., Кононов А.В., Мозговой С.И. Постэрадикационный период хронического гастрита, ассоциированного с инфекцией Helicobacter pylori. Consilium Medicum. 2008;10(8):15-20.
- Ford A.C, Forman D, Hunt R.H, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta - analysis of randomised controlled trials. BMJ. 2014;348:g3174. doi: 10.1136/bmj.g3174
- Matysiak-Budnik T, Megraud F. Helicobacter pylori infection and gastric cancer. Eur J Cancer. 2006;42(6):708-16. doi: 10.1016/j.ejca.2006.01.020
- Kalisperati P, Spanou E, Pateras I.S et al. Inflammation, DNA Damage, Helicobacter pylori and Gastric Tumorigenesis. Front Genet. 2017;8:20. doi: 10.3389/fgene.2017.00020
- Graham D.Y, Matsueda S, Shiotani A. Changing the natural history of metachronous gastric cancer after H. pylori eradication. Jpn J Helicobacter Res. 2015;16:42-50.
- Correa P. The biological model of gastric carcinogenesis. IARC Sci Publ. 2004;157:301-11.
- Demiray M, Gulten M, Manavoglu O et al. Evaluation of the effects of Helicobacter pylori eradication therapy on gastric antral epithelial hyperproliferation: a prospective six - month follow - up study. Hepatogastroenterology. 2004;51(59):1531-5.
- Кононов А.В., Ливзан М.А., Мозговой С.И. Гастрит после эрадикации: экс - геликобактерный или постэрадикационный? В кн.: Тезисы докладов Х Российского национального конгресса «Человек и лекарство». М., 2003.
- Shimada M, Ina K, Kyokane K, et al. Upregulation of mucosal soluble fas ligand and interferon - gamma may be involved in ulcerogenesis in patients with Helicobacter pylori - positive gastric ulcer. Scand J Gastroenterol. 2002;37(5):501-11. doi: 10.1080/00365520252903026
- Маев И.В. Современные представления о заболеваниях желудочно - кишечного тракта, ассоциированных с Helicobacter pylori. Терапевтический архив. 2006;78(2):10-5.
- Osawa H, Kita H, Ohnishi H, Mutoh H, Ishino Y, Satoh K, Sugano K. Histamine-2 receptor expression in gastric mucosa before and after Helicobacter pylori cure. Aliment Pharmacol Ther. 2005;21(Suppl.2):92-8. doi: 10.1111/j.1365-2036.2005.02481.x
- Cheung K.S, Leung W.K. Risk of gastric cancer development after eradication of Helicobacter pylori. World J Gastrointest Oncol. 2018;10(5):115-23. doi: 10.4251/wjgo.v10.i5.115
- Correa P. Human gastric carcinogenesis: a multistep and multifactorial process - First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992;52:6735-40.
- Correa P, Piazuelo M.B, Camargo M.C. The future of gastric cancer prevention. Gastric Cancer. 2004;7:9-16. doi: 10.1007/s10120-003-0265-0
- Маев И.В., Самсонов А.А., Андреев Д.Н., Гречушников В.Б., Коровина Т.И. Клиническое значение инфекции Helicobacter pylori. Клиническая медицина. 2013;91(8):4-12.
- Han X, Jiang K, Wang B, et al. Effect of Rebamipide on the Pre - malignant Progression of Chronic Gastritis: A Randomized Controlled Study. Clin Drug Investig. 2015;35(10):665-73. doi: 10.1007/s40261-015-0329-z
- Tanigawa T, Pai R, Arakawa T, Tarnawski A.S. Rebamipide inhibits gastric cancer cell growth. Dig Dis Sci. 2007;52(1):240-7. doi: 10.1007/s10620-006-9226-x
- Tsukamoto H, Mizoshita T, Katano T, Hayashi N, Ozeki K, Ebi M, Shimura T, Mori Y, Tanida S, Kataoka H, Tsukamoto T, Tatematsu M, Joh T. Preventive effect of rebamipide on N-methyl-N’-nitro-N-nitrosoguanidine - induced gastric carcinogenesis in rats. Exp Toxicol Pathol. 2015;67(3):271-7. doi: 10.1016/j.etp.2015.01.003
- Маев И.В., Кучерявый Ю.А., Андреев Д.Н., Баркалова Е.В. Эрадикационная терапия инфекции Helicobacter pylori: обзор мировых тенденций. Терапевтический архив. 2014;86(3):94-9.
- Андреев Д.Н., Маев И.В., Дичева Д.Т., Самсонов А.А., Парцваниа-Виноградова Е.В. Эффективность и безопасность применения ребамипида в схеме тройной эрадикационной терапии инфекции Helicobacter pylori: проспективное рандомизированное сравнительное исследование. Терапевтический архив. 2018;90(8):27-32. doi: 10.26442/terarkh201890827-32